New diabetes drug HM11260C aims to lower blood sugar in patients not helped by standard meds
NCT ID NCT07379333
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tests a new drug called HM11260C for adults with type 2 diabetes whose blood sugar is still too high despite taking metformin and dapagliflozin. About 118 participants will receive either the new drug or a placebo for 36 weeks to see if it safely lowers HbA1c levels. The goal is to improve blood sugar control, not cure diabetes, so ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea Bucheon St. Mary's Hospital
RECRUITINGGyeonggi-do, South Korea
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.